Cover Story
By Matthew Bin Han Ong
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Rathmell steps down at NCI as Trump team considers candidates to replace her
Wafik El-Deiry, Harvey Risch have been interviewed - As fire encroached, City of Hope prepared to evacuate its Duarte campus
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - NCCN publishes patient resource on genetic testing to guide patient decisionmaking
- Trump 2016: A look back at the 45th president’s impact on oncology
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities